This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fedorov, V. Articles by Jones, B. Search for Related Content PubMed PubMed Citation Articles by Fedorov, V. Articles by Jones, B. Social Bookmarking                         What's this?

The design of multicentre trials

Research Statistics Unit, GlaxoSmithKline Pharmaceuticals, Philadelphia, PA, USA

Byron Jones

Statistical Research and Consulting Centre, Pfizer Global Research and Development, Sandwich, Kent, UK, byron.jones{at}pfizer.com

The analysis of data collected in multicentre trials offers challenges because the data from the individual centres must be combined in some way to give an overall evaluation of the differences between the treatments in the trial. We propose that the combined response to treatment (CRT) be used as this overall measure. The definition and estimation of the CRT can be derived from either a fixed-effects or a random-effects model. For the latter we introduce the ECRT - the expected combined response to treatment. We describe and compare both types of model and express our preference for the random-effects model. We stress that the number of patients enrolled at a centre is a random variable and show that this source of randomness inflates the variance of the estimated ECRT. Variability in enrolment rates over the centres further inflates this variance. A simple conclusion from our results is that if variability in the treatment and centre effects, in the enrolment time, in the number of patients enrolled at a centre and in the enrolment rates is not properly accounted for, then an underpowered trial may result. Using properties of estimators generated by the random-effects model we propose methods for determining the optimal number of centres and total number of patients to enrol in a trial to minimize a loss function that accounts for centre and patient costs and loss of revenue. We discuss variants of the loss function and corresponding optimization problems for different types of enrolment. We end the paper with brief generalizations of the developed techniques to the case where the response is binary.

Statistical Methods in Medical Research, Vol. 14, No. 3, 205-248 (2005)
DOI: 10.1191/0962280205sm399oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Brok, K. Thorlund, J. Wetterslev, and C. Gluud Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses Int. J. Epidemiol., February 1, 2009; 38(1): 287 - 298. [Abstract] [Full Text] [PDF]

				G. J. van Breukelen, M. J. Candel, and M. P. Berger Relative efficiency of unequal cluster sizes for variance component estimation in cluster randomized and multicentre trials Statistical Methods in Medical Research, August 1, 2008; 17(4): 439 - 458. [Abstract] [PDF]